Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Post by stocksarefunon Oct 30, 2021 8:46am
158 Views
Post# 34067443

Should we enter phase 3....

Should we enter phase 3....I have never owned a ticker that has moved from phase 2 to phase 3. 

For those who have been down this road before, what are the likely next steps?

- Is dilution and a big capital raise to fund the next next trials normal at these stages?
- How likely is it that the government of canada continue to grant funds?
- Does it require additional headcount?
- Is there another step between where we are at and launch of phase 3? (announcement of phase 3 design parameters, and disclosure of what's needed for it to commence, for example?)
- Does the announcement of Phase 3 and the announcement of funds being raised come in the same press release, of staggered?
- Do we generally see a wave of volume come in, simply by ARCH now being taken more seriously by US investors?

I'd love to start a discussion around what risks would present themselves in the short term, that could be used against us in creating wild volatile swings in the coming months as we progress down this path. 

Congratulations to everyone who has held on thus far. 
<< Previous
Bullboard Posts
Next >>